Elcelyx Therapeutics: Elcelyx unveils positive results in phase 2b study of Metformin DR in type 2 diabetes

Elcelyx Therapeutics announced today that its Phase 2b doseranging study met the primary endpoint of showing a statistically significant reduction in HbA1c at 16 weeks with Metformin Delayed Release (Metformin DR) compared with placebo in subjects with type 2 diabetes.The post Elcelyx unveils positive results in phase 2b study of Metformin DR in type 2 diabetes appeared first on PharmaLeaders.com.